drytec tm -
ge healthcare b.v. - natriummolybdat mo-99 omdannes til natriumperteknetat tc-99m - radionuklidegenerator
milbemax vet 2.5 mg / 25 mg
elanco gmbh - milbemycinoksim / prazikvantel - tablett - 2.5 mg / 25 mg
milbemax vet 12.5 mg / 125 mg
elanco gmbh - milbemycinoksim / prazikvantel - tablett - 12.5 mg / 125 mg
milbemax vet 4 mg / 10 mg
elanco gmbh - milbemycinoksim / prazikvantel - tablett, filmdrasjert - 4 mg / 10 mg
milbemax vet 16 mg / 40 mg
elanco gmbh - milbemycinoksim / prazikvantel - tablett, filmdrasjert - 16 mg / 40 mg
milbemax vet 2.5 mg / 25 mg
elanco gmbh - milbemycinoksim / prazikvantel - tyggetablett - 2.5 mg / 25 mg
milbemax vet 12.5 mg / 125 mg
elanco gmbh - milbemycinoksim / prazikvantel - tyggetablett - 12.5 mg / 125 mg
givlaari
alnylam netherlands b.v. - givosiran - porfyrier, nedsatt - ulike alimentary tract and metabolism products - behandling av akutt hepatisk porfyri (ahp) i voksne og ungdom i alderen 12 år og eldre.
azacitidine mylan
mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.
clopidogrel acino
acino ag - klopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.